(E)-1-(naphthalen-2-yl)-3-(p-tolyl)prop-2-en-1-one | 62918-33-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-1-(naphthalen-2-yl)-3-(p-tolyl)prop-2-en-1-one
• 英文别名: (E)-1-(2-naphthyl)-3-(p-tolyl)prop-2-en-1-one；(E)-3-(4-methylphenyl)-1-naphthalen-2-ylprop-2-en-1-one
• CAS: 62918-33-6
• 化学式: C₂₀H₁₆O
• 分子量: 272.346
• InChiKey: JVNDANVFXSSNPL-JLHYYAGUSA-N

物化性质

• 熔点：
  147 °C(Solv: ethyl ether (60-29-7))
• 沸点：
  454.4±38.0 °C(Predicted)
• 密度：
  1.133±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (E)-1-(naphthalen-2-yl)-3-(p-tolyl)prop-2-en-1-one 在 sodium ethanolate 、 sodium acetate 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 9.0h， 生成 4,5-dihydro-6-naphthalen-2-yl-4-p-tolyl-2H-indazol-3-ol
  参考文献：
  名称：

  Synthesis, spectral analysis and in vitro microbiological evaluation of novel ethyl 4-(naphthalen-2-yl)-2-oxo-6-arylcyclohex-3-enecarboxylates and 4,5-dihydro-6-(napthalen-2-yl)-4-aryl-2H-indazol-3-ols

  摘要：

  A series of ethyl 4-(naphthalen-2-yl)-2-oxo-6-arylcyclohex-3-enecarboxylates 8--14 and 4,5-dihydro-6-(naphthalen-2-yl)-4-aryl-2H-indazol-3-ols 15--21 were synthesised and characterised by their spectroscopic data. In vitro microbiological evaluations were carried out for all the newly synthesised compounds 8--21 against clinically isolated bacterial and fungal strains. Compounds 9, 12 and 20 against Staphylococcus aureus, 10, 12, 20 against beta beta-haemolytic streptococcus, 11, 17 against Bacillus subtilis, 12, 16 and 20 against Vibreo cholerae, 13, 16 against Escherichia coli, 13, 16, 18, 19 against Salmonella typhii, 12, 18 against Shigella flexneri, 10 against Salmonella typhii, 10, 13, 17, 18 against Aspergillus flavus, 12, 17, 21 against Aspergillus niger, 12, 15, 17, 18, 20 against Mucor, Rhizopus and Microsporeum gypsuem exhibit potent antimicrobial activity.

  DOI：

  10.3109/14756361003689856
• 作为产物：
  描述：

  对甲基苯甲醛 、 2-萘乙酮 在 氯化锆(IV) 作用下， 以 乙醇 为溶剂， 反应 7.0h， 以87%的产率得到(E)-1-(naphthalen-2-yl)-3-(p-tolyl)prop-2-en-1-one
  参考文献：
  名称：

  ZrCl4作为环酮与芳香醛在回流乙醇中的交叉羟醛缩合的高效催化剂

  摘要：

  描述了环酮与芳香醛在乙醇中在回流条件下使用 ZrCl 4 作为催化剂的羟醛缩合反应，以优异的收率得到相应的 α,α'-双（取代的亚苄基和亚桂基）环烷酮。没有产生自缩合产物。

  DOI：

  10.1002/jccs.200700117

文献信息

• Asymmetric Conjugate Addition of Organoboron Reagents to Common Enones Using Copper Catalysts
  作者：Chunlin Wu、Guizhou Yue、Christian Duc-Trieu Nielsen、Kai Xu、Hajime Hirao、Jianrong (Steve) Zhou

  DOI：10.1021/jacs.5b11441

  日期：2016.1.27

  Copper complexes of phosphoramidites efficiently catalyzed asymmetric addition of arylboron reagents to acyclic enones. Importantly, rare 1,4-insertion of arylcopper(I) was identified which led directly to O-bound copper enolates. The new mechanism is fundamentally different from classical oxidative addition/reductive elimination of organocopper(I) on enones.

  亚磷酰胺的铜配合物有效地催化芳基硼试剂向无环烯酮的不对称加成。重要的是，鉴定了稀有的芳基铜（I）的 1,4-插入，这直接导致了与 O 结合的铜烯醇化物。新机制与传统的有机铜（I）在烯酮上的氧化加成/还原消除有着根本的不同。
• ALLOSTERIC PROTEIN KINASE MODULATORS
  申请人：Engel Matthias

  公开号：US20120046307A1

  公开（公告）日：2012-02-23

  The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

  本发明提供了特定的小分子化合物，它们通过变构调节AGC蛋白激酶的活性或调节Aurora家族蛋白激酶的蛋白质-蛋白质相互作用，其生产方法，包含该化合物的药物组合物，以及它们用于制备治疗和预防与AGC蛋白激酶或Aurora家族蛋白激酶异常活动相关疾病的药物的应用。
• Effects of Structural and Electronic Characteristics of Chalcones on the Activation of Peroxisome Proliferator-Activated Receptor Gamma
  作者：Jason Taylor Schott、Charles Edward Mordaunt、Anthony Joseph Vargas、Martin Antonio Leon、Kevin Hsinwen Chen、Mandeep Singh、Mikiko Satoh、Emilio Leal Cardenas、Santanu Maitra、Nilay Vinod Patel、Hubrecht Johan Peter de Lijser

  DOI：10.1248/cpb.c12-00749

  日期：——

  chalcones with an electron rich group or sterically large groups such as naphthyl on the carbonyl side tend to activate PPARγ. The absence of any strict structural or electronic requirements suggests that the flexibility of the PPARγ ligand binding pocket may allow binding of diverse chalcones with some preference for a slightly larger electron-rich group on the carbonyl side. We predict that further structure-activity

  Chalcones与GW-1929具有一些结构相似性，GW-1929是一种过氧化物酶体增殖物激活的受体-γ（PPARγ）的高选择性强效激动剂。在这项研究中，我们测试了53种结构多样的查耳酮，以鉴定基于GAL4的反式激活分析中PPARγ激活所必需的特征。该屏幕鉴定了几种新颖的PPARγ查尔酮激动剂。我们的结果表明，在羰基侧具有富电子基团或空间较大基团（例如萘基）的查耳酮倾向于激活PPARγ。缺乏任何严格的结构或电子要求表明，PPARγ配体结合口袋的柔韧性可能允许各种查耳酮的结合，并且偏向于羰基侧稍大的富电子基团。
• Domino-Fluorination–Protodefluorination Enables Decarboxylative Cross-Coupling of α-Oxocarboxylic Acids with Styrene via Photoredox Catalysis
  作者：Muliang Zhang、Junwei Xi、Rehanguli Ruzi、Nan Li、Zhongkai Wu、Weipeng Li、Chengjian Zhu

  DOI：10.1021/acs.joc.7b01054

  日期：2017.9.15

  a carbon-centered radical intermediate, which will overcome side reactions during the styrene radical functionalization process. Experimental studies have provided evidence indicating a domino-fluorination–protodefluorination pathway with α-keto acid initiating the photoredox cycle. The present catalytic protocol also affords a novel approach for the construction of α,β-unsaturated ketones under mild

  通过光氧化还原催化，已经开发出α-酮酸与苯乙烯的多米诺氟化-原脱氟脱羧交叉偶联。该策略的关键部分是通过捕获以碳为中心的自由基中间体形成碳-氟（C-F）键，这将克服苯乙烯自由基官能化过程中的副反应。实验研究提供了证据，表明具有α-酮酸的多米诺氟化-原脱氟途径可引发光氧化还原循环。本催化方案还提供了在温和条件下构建α，β-不饱和酮的新方法。
• Chalcones: As Potent α-amylase Enzyme Inhibitors; Synthesis, In Vitro, and In Silico Studies
  作者：Mahboob Ali、Momin Khan、Khair Zaman、Abdul Wadood、Maryam Iqbal、Aftab Alam、Sana Shah、Ashfaq Ur Rehman、Muhammad Yousaf、Rafaila Rafique、Khalid Mohammed Khan

  DOI：10.2174/1573406416666200611103039

  日期：2021.9.10

  EI-MS, HRESI-MS, 1H-, and 13C-NMR. Results: Sixteen synthetic chalcones were evaluated for in vitro porcine pancreatic α-amylase inhibition. All the chalcones demonstrated good inhibitory activities in the range of IC50 = 1.25 ± 1.05 to 2.40 ± 0.09 μM as compared to the standard commercial drug acarbose (IC50 = 1.34 ± 0.3 μM). Conclusion: Chalcone derivatives (1-16) were synthesized, characterized,

  背景：抑制α-淀粉酶是治疗II型糖尿病的最佳治疗方法之一。查尔酮具有广泛的生物活性。 目的：在目前的研究中，合成了查耳酮衍生物 (1-16) 并评估了它们对 α-淀粉酶的抑制潜力。 方法：为此，通过 2-乙酰萘酮和取代芳基的 Claisen-Schmidt 缩合反应合成了取代 (E)-1-(naphthalene-2-yl)-3-phenylprop-2-en-1-ones 库苯甲醛在碱存在下并通过不同的光谱技术表征，如 EI-MS、HRESI-MS、1 H-和13 C-NMR。 结果：评估了 16 种合成查耳酮对体外猪胰腺 α-淀粉酶的抑制作用。与标准商业药物阿卡波糖 (IC 50 = 1.34 ± 0.3 μM)相比，所有查耳酮在 IC 50 = 1.25 ± 1.05 至 2.40 ± 0.09 μM范围内均表现出良好的抑制活性。 结论： 查尔酮衍生物 (1-16) 已合成、表征并评估其